
X
ESMO 2017 round up: BMS and AZ bounce back
https://pharmaphorum.com/news/esmo-2017-round-bms-az-bounce-back/
Clovis’ Rubraca, the drug showing significant benefits for all ovarian cancer patients in a maintenance setting – and better results than its rivals.
A look ahead at some of the most eye-catching data and trends at ESMO 2017
Roche’s Alecensa has shown strong results in two studies looking at its benefits in ALK positive non-small cell lung cancer (NSCLC) patients, both in first line use and a second line setting.